Angina, Unstable
Eptifibatide
Heparin
Non-ST Elevated Myocardial Infarction
Percutaneous Coronary Intervention

Eptifibatide

Eptifibatide is a glycoprotein IIb/IIIa class platelet inhibitor drug that reduces ischemic cardiac events in specific patient populations. The FDA has approved this medication for the medical management of unstable angina and non-ST elevation myocardial infarction (NSTEMI). The FDA also approved eptifibatide for patients undergoing percutaneous intervention (PCI), including intracoronary stenting. The IMPACT-II trial proved that eptifibatide use with heparin and aspirin reduces ischemic events following a PCI, especially in individuals with unstable angina. This activity outlines the indications, mechanism of action, administration, adverse effects, contraindications, warnings, precautions, monitoring, and toxicity of eptifibatide. Participating clinicians understand eptifibatide’s role in emergency and chronic medical care, highlighting significant risks of bleeding and thrombocytopenia, which require vigilant monitoring by the interprofessional healthcare team. Effective communication and collaboration among team members, including specialists and ordering clinicians, are essential for optimizing therapeutic outcomes with eptifibatide and differentiating potential complications like heparin-induced thrombocytopenia (HIT).

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.